scholarly journals Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients

Gut and Liver ◽  
2015 ◽  
Vol 9 (3) ◽  
Author(s):  
Shen Shong Chang ◽  
Hsiao-Yun Hu
Keyword(s):  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
Ulcer Bleeding ◽  
Peptic Ulcers ◽  
Peptic Ulcer Bleeding ◽  
Helicobacter Pylori Eradication

EFFICACY OF INITIAL AND PERMANENT HEMOSTASIS OF THE ENDOSCOPIC HEMOCLIP METHOD COMBINED WITH HIGH-DOSE INFUSION OF PROTON PUMP INHIBITOR IN PATIENTS WITH PEPTIC ULER BLEEDING

2018 ◽  
pp. 15-21
Author(s):  
Hieu Tam Huynh ◽  
Dang Quy Dung Ho
Keyword(s):  
Peptic Ulcer ◽  
Success Rate ◽  
Endoscopic Hemostasis ◽  
Ulcer Bleeding ◽  
Injection Sclerotherapy ◽  
High Dose ◽  
Peptic Ulcers ◽  
Peptic Ulcer Bleeding ◽  
Bleeding Peptic Ulcers ◽  
Hemostatic Therapy

Background: Peptic ulcer bleeding is one of the common medical emergencies. The hemostatic efficacy of endoscopic therapeutic modalities has been reported in many studies and frequently has been found to exceed 90%. Four groups of modalities are used in the endoscopic management of bleeding peptic ulcers: thermal probe methods, injection sclerotherapy, local spray methods, and mechanical hemostatic therapy. The endoscopic hemoclip method is a safe and effective hemostatic therapy for managing bleeding peptic ulcers. Objective: To determine the success rate of hemoclip in endoscopic hemostasis. Patients and methods: Clinical intervention study on 36 patients with peptic ulcer bleeding admitted in Can Tho Central General Hospital from May 2012 to November 2014. All the patients underwent emergency endoscopy for hemostasis by hemoclip and high-dose PPI use. Results: The success rate of initial hemostasis was 97.2%, and permanent hemostasis was 91.7%. The rates of rebleeding, surgery, mortality were 11.1%, 5.6%, 2.8%, respectively. Conclusion: Endoscopic hemostasis therapy by clipping combined with high- dose PPI is an effective, relatively safe treatment for peptic ulcer bleeding. Key words: Peptic ulcer bleeding, hemoclip, endoscopic hemostasis therapy

Will Helicobacter Pylori Affect Short-Term Rebleeding Rate in Peptic Ulcer Bleeding Patients After Successful Endoscopic Therapy?

1999 ◽  
Vol 94 (11) ◽  
pp. 3184-3188 ◽  
Author(s):  
Hwai-Jeng Lin ◽  
Guan-Ying Tseng ◽  
Yu-Hsi Hsieh ◽  
Chin-Lin Perng ◽  
Fa-Yauh Lee ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
Endoscopic Therapy ◽  
Ulcer Bleeding ◽  
Peptic Ulcer Bleeding ◽  
Short Term ◽  
Rebleeding Rate

scholarly journals Various aspects of peptic ulcer in patients with liver cirrhosis

2018 ◽  
Vol 71 (1-2) ◽  
pp. 27-32
Author(s):  
Zeljka Savic ◽  
Dragomir Damjanov ◽  
Vladimir Vracaric ◽  
Dijana Kosijer ◽  
Dimitrije Damjanov ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Liver Cirrhosis ◽  
Peptic Ulcer ◽  
Helicobacter Pylori Infection ◽  
Ulcer Bleeding ◽  
Peptic Ulcer Bleeding ◽  
Cirrhotic Patients ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Bleeding Ulcers

Introduction. The occurrence of peptic ulcer in patients with liver cirrhosis is intriguing due to its frequency and complexity. The aim of the present study was to investigate the incidence of peptic ulcer in patients with liver cirrhosis. Results. It was found that in these patients the usual aggressive factors of the gastric environment do not play a major role in ulcerogenesis; however, researches noticed the importance of reduced mucosal defense which, in portal hypertension, has the features of hypertensive portal gastropathy. The presence of Helicobacter pylori infection in these patients is lower, compared to other patients with peptic ulcer. The prevalence of Helicobacter pylori infection decreases with the severity of liver cirrhosis. Non-steroidal anti-inflammatory drugs play an important role in peptic ulcer bleeding in cirrhotic patients, but the data are limited and contradictory. Peptic ulcer bleeding is the most frequent etiology of nonvariceal bleeding and it is associated with a great number of complications. Conclusion. Helicobacter pylori infection cannot be considered the key risk factor for the development of peptic ulcer in patients with liver cirrhosis. The role of non-steroidal anti-inflammatory drugs is accepted, although the data are controversial. The treatment of peptic ulcer in cirrhotic patients is identical to the treatment of peptic ulcer in patients without liver cirrhosis, except in cases of bleeding ulcers. There are specific therapeutic protocols for peptic ulcer bleeding in patients with liver cirrhosis.

Sign in / Sign up

Export Citation Format

Share Document